USA flag logo/image

An Official Website of the United States Government

Development of manufacturing technology for the practical application of…

Award Information

Agency:
Department of Commerce
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
12-081
Solicitation Year:
2012
Solicitation Topic Code:
8.2.3F
Solicitation Number:
1
Small Business Information
Zeigler Bros, Inc.
PO Box 95 Gardners, PA 17324-0095
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Development of manufacturing technology for the practical application of specialized and environmentally sensitive nutrients, enzymes, immune-stimulating compounds and biologics to aquafeeds
Agency: DOC
Contract: WC-133R-12-CN-0069
Award Amount: $82,133.56
 

Abstract:

Zeigler Bros., Inc. (ZBI) has teamed with Harrisvaccines, Inc. (HV) to develop a new aquafeed manufacturing platform for the practical application of underutilized feed additives. These include enzymes, immune-stimulating compounds and biologics that require specialized protection to ensure they are delivered to the animal as viable compounds. ZBI pioneered microparticle feeds and will use this technology to manufacture inclusion particles capable of stabilizing these underutilized additives. RNA interference (RANi) is a promising, emerging technology that has demonstrated a range of applications in aquaculture as an antiviral/immune-stimulating compound. It is proposed that double-stranded RNA (dsRNA) constitute the RNAi effector molecules that provide that antiviral effect. Furthermore, RNA provides and environmentally sensitive model that has a pre-existing base for molecular assays for detection. HV can produce large-scale amounts of RNA that make a commercially feasible feed additive and they have shown that these RNA molecules can protect against lethal White Spot Syndrome Virus (WSSV) challenge. The immediate impact from a successful Phase I project will be the first candidate orally delivered molecular WSSV vaccine for clinical trial. With subsequent Phase II funding ZBI and HV will qualify this platform for effectiveness in controlling other aquaculture diseases, reducing effluents and increasing nutrient utilization.

Principal Investigator:

Scott Snyder, Ph.D
(717) 677-3013
scott.snyder@zieglerfeed.com
Small Business Information at Submission:

Zeigler Brothers, Inc.
P.O. Box 95 Gardners, PA 17324-0095

EIN/Tax ID: 231321071
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No